Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Datopotamab deruxtecan ± Durvalumab in PD-L1-negative metastatic triple-negative breast cancer
KCT0010796Phase 2Not yet recruiting
- Sponsor
- Queen Mary University of London
- Start
- Dec 2025
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of datopotamab deruxtecan, durvalumab in breast cancer, sponsored by Queen Mary University of London. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
datopotamab deruxtecandurvalumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on KCT0010796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010796.